Showing results (1-10 of 248) with videos related to
Sort By:
Pageof 25
Drugs|May 28, 2024
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons LearnedSarah A Jones, Eric F MorandMed (New York, N.Y.)|July 10, 2026
Systemic lupus erythematosus: Phase 2 trials to watch in 2026Eric F Morand, Sarah A JonesTrends in Molecular Medicine|July 10, 2025
10 years in lupus - progress, but not enoughEric F Morand, Sarah A JonesExpert Opinion on Biological Therapy|July 22, 2025
Progress in the use of type I interferon blockade in systemic lupus erythematosusIolanda Miceli, Eric F Morand, Sarah A JonesImmunology and Cell Biology|July 23, 2014
GILZ: a new link between the hypothalamic pituitary adrenal axis and rheumatoid arthritis?Laura E Eades, Angeline S Thiagarajah, James Harris, et al.Journal of Autoimmunity|June 17, 2015
GILZ regulates Th17 responses and restrains IL-17-mediated skin inflammationSarah A Jones, Diluptha N Perera, Huapeng Fan, et al.Current Opinion in Rheumatology|April 7, 2007
Effects of glucocorticoids on inflammation and arthritisEric F MorandThe Lancet. Rheumatology|January 27, 2024
Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro studyMelissa Northcott, Linden J Gearing, Hieu T Nim, et al.Internal Medicine Journal|August 23, 2021
Systemic lupus erythematosus: a clinical updateKathryn Connelly, Eric F MorandInternational Journal of Rheumatic Diseases|April 18, 2015
Optimizing the use of existing therapies in lupusLucy Croyle, Eric F MorandPageof 25